Approximately 80 percent of patients with bladder cancer showed a reduction in tumor size, with no reported side effects ...

PleoPharma, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PP-01, the company’s lead investigational asset aimed at mitigating Cannabis ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Schrödinger faces financial losses amid investment in experimental drugs. Key 2025 trial results will reveal its future ...

Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that the U.S. Food and Drug Administration (FDA) ...

Received overwhelming shareholder support in favour of take-private transaction with AditxtAdvanced key pipeline programs, engaged regulatory ...

A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. | The new FDA approval gives ...

Vistagen Therapeutics, Inc.'s fasedienol shows promise in treating social anxiety; new results expected 2025. Click for my ...

Last year was a pivotal year for the pharmaceutical industry. Under the IRA’s Medicare Drug Price Negotiation Program (the ...

Researchers identified three new all-oral drug regimens that include at least one of two new drugs for treatment of ...

HER2, a HER2-targeted immunotherapy, with plans for FDA submission following promising Phase 2b data in osteosarcoma.